Floatz logo

Vinblastine

Urinary Bladder Carcinoma

University of Southern CaliforniaSmall moleculePhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
73/ 100

Competitive context

121 Active assets in the Urinary Bladder Carcinoma cohort.

Asset / SponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
G1 Therapeutics, Inc.
Phase 3BBB
Trastuzumab
NKGen Biotech, Inc.
Phase 2BB
Carboplatin
G1 Therapeutics, Inc.
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 3BB
Pembrolizumab
Essen Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

Vinblastine is also rated in:

renal pelvis/ureter urothelial carcinomaDormant
BBB
Indicative · Phase 3
73 / 100
View asset →
carcinoma of urethraDormant
BBB
Indicative · Phase 3
73 / 100
View asset →
Hodgkins lymphomaActive
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →